Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients

References

• Aguiar P.N., Tadokoro H., da Silva G.F., Landgraf M.M., Noia Barreto C.M., et al. 2016. Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. Future Oncol, 12, 2755–2764.
   PubMed Web of Science ®Google Scholar
• American Speech-Language-Hearing Association. 1994. Audiologic management of individuals receiving cochleotoxic drug therapy. Retrieved: http://www.asha.org/policy/GL1994-00003.htm.
   Google Scholar
• Bauer F.P., Westhofen M. & Kehrl W. 1992. The ototoxicity of the cytostatic drug carboplatin in patients with head–neck tumors. Laryngorhinootologie, 71, 412–415.
   PubMed Web of Science ®Google Scholar
• Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefebvre J.L., et al. 2004. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med, 350, 1945–1952.
   PubMed Web of Science ®Google Scholar
• Bhandare N., Antonelli P.J., Morris C.G., Malayapa R.S. & Mendenhall W.M. 2007. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys, 67, 469–479.
   PubMed Web of Science ®Google Scholar
• Cheraghi S., Nikoofar P., Fadavi P., Bakhshandeh M., Khoie S., et al. 2015. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy. Med Oncol, 32, 200.
   PubMed Web of Science ®Google Scholar
• Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., et al. 2004. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med, 350, 1937–1944.
   PubMed Web of Science ®Google Scholar
• De Serdio J.L., Villar A., Halawa B.F., Gonzalez-Castro I., Alvarez I.E., et al. 1997. Auditory assessment in a protocol of concurrent carboplatin and irradiation use in fractionated therapy. Acta Otorrhinolaryngol Esp, 48, 614–619.
   PubMedGoogle Scholar
• Hitchcock Y.J., Tward J.D., Szabo A., Bentz B.G. & Shrieve D.C. 2009. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys, 73, 779–788.
   PubMed Web of Science ®Google Scholar
• Hua C., Bass J.K., Khan R., Kun L.E. & Merchant T.E. 2008. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys, 72, 892–899.
   PubMed Web of Science ®Google Scholar
• Husain K., Whitworth C., Somani S.M. & Rybak L.P. 2005. Partial protection by lipoic acid against carboplantin-induced ototoxicity in rats. Biomed Environ Sci, 18, 198–206.
   PubMed Web of Science ®Google Scholar
• Husain Z.A., Burtness B.A. & Decker R.H. 2016. Cisplatin versus cetuximab with radioatherapy in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol, 34, 396–399.
   PubMed Web of Science ®Google Scholar
• Hwang C.-F., Fang F.-M., Zhuo M.-Y., Yang C.-H., Yang L.-N., et al. 2015. Hearing assessment after treatment of nasopharyngeal carcinoma with CRT and IMRT techniques. BioMed Res Int, 2015, 769806.
   PubMed Web of Science ®Google Scholar
• Ishikawa E., Sugimoto H., Hatano M., Nakanishi Y., Tsuji A., et al. 2015. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer. Acta Oto-Laryngologica, 135, 919–924.
   PubMed Web of Science ®Google Scholar
• Lee T.F., Yeh S.A., Chao P.J., Chang L., Chiu C.L., et al. 2015. Normal tissue complication probability modeling for cochlea constraints to avoid causing tinnitus after head-and-neck intensity-modulated radiation therapy . Radiat Oncol, 10, 194.
   PubMed Web of Science ®Google Scholar
• Low W.K., Toh S.T., Wee J., Fook-Chong S.M.C. & Wang D.Y. 2006. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol, 24, 1904–1908.
   PubMed Web of Science ®Google Scholar
• Marks L.B., Yorke E.D., Jackson A., Ten Haken R.K., Constine L.S., et al. 2010. Use of normal tissue complication probability models in the clinic. Int J Radiation Oncology Biol Phys, 76, S10–S19.
   PubMed Web of Science ®Google Scholar
• Melotek J.M., Cooper B.T., Koshy M., Silverman J.S. & Spiotto M.T. 2016. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol Head Neck Surg, 45, 62.
   PubMed Web of Science ®Google Scholar
• Mujica-Moto M., Waissbluth S. & Daniel S.J. 2013. Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review. Head Neck, 35, 1662–1668.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. 2010. National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Retrieved: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
   Google Scholar
• Niemensivu R., Saarilahti K., Ylikoski J., Aarnisalo A. & Makitie A.A. 2016. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy. Eur Arch Otorhinolaryngol, 273, 2509–2514.
   PubMed Web of Science ®Google Scholar
• Pan C.C., Eisbruch A., Lee J.S., Snorrason R.M., Ten Haken R.K., et al. 2005. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiation Oncology Biol Phys, 61, 1393–1402.
   PubMed Web of Science ®Google Scholar
• Pearson S.E., Meyer A.C., Adams G.L. & Ondrey F.G. 2006. Decreased hearing after combined modality therapy for head and neck cancer. Am J Otolaryngol, 27, 76–80.
   PubMed Web of Science ®Google Scholar
• Rades D., Fehlauer F., Sheikh-Sarraf M., Kazic N., Basic H., et al. 2008. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck, 30, 235–241.
   PubMed Web of Science ®Google Scholar
• Theunissen E.A., Zuur C.L., Lopez Yurda M., van der Baan S., Kornman A.F., et al. 2014. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study. J Otolaryngol Head Neck Surg, 43, 30.
   PubMed Web of Science ®Google Scholar
• Theunissen E.A., Bosma S.C., Zuur C.L., Spijker R., van der Baan S., et al. 2015a. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck, 37, 281–292.
   PubMed Web of Science ®Google Scholar
• Theunissen E.A., Zuur C.L., Jozwiak K., Lopez-Yurda M., Hauptmann M., et al. 2015b. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy. JAMA Otolaryngol Head Neck Surg, 141, 810–815.
   PubMed Web of Science ®Google Scholar
• Walker G.V., Ahmed S., Allen P., Gidley P.W., Woo S.Y., et al. 2011. Radiation-induced middle ear and mastoid opacificaiton in skull base tumors treated with radiotherapy. Int J Radiation Oncology Biol Phys, 81, e819–e823.
   PubMed Web of Science ®Google Scholar
• Zuur C.L., Simis Y.J., Lansdaal P.E., Hart A.A., Rasch C.R., et al. 2007a. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiation Oncology Biol Phys, 68, 1320–1325.
   PubMed Web of Science ®Google Scholar
• Zuur C.L., Simis Y.J., Lansdaal P.E., Hart A.A., Schornagel J.H., et al. 2007b. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol, 25, 3759–3765.
   PubMed Web of Science ®Google Scholar
• Zuur C.L., Simis Y.J., Lamers E.A., Hart A.A., Dreschler W.A., et al. 2009. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors. Int J Radiation Oncology Biol Phys, 74, 490–496.
   PubMed Web of Science ®Google Scholar